RT @ScienceofPD: The rationale, design, & baseline data for the @roche @ProthenaCorp Phase II study evaluating the safety & efficacy of Pra…
3,882 followers
10,334 followers
The rationale, design, & baseline data for the @roche @ProthenaCorp Phase II study evaluating the safety & efficacy of Prasinezumab (an alpha-synuclein targeting immunotherapy) in early #Parkinsons (the PASADENA study) has been published https://t
925 followers
New article: A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data https://t.co/yQQq5B8vlX #MDS #mdssm #hematology https://t.co/nUikjdObZm
444 followers
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data https://t.co/pV46gMC2Fg #Parkinson #neurologia